A study to find out if the study drug elecoglipron helps adults with type 2 diabetes mellitus by comparing it with semaglutide, a medicine already used to treat type 2 diabetes mellitus - Eluminate-2

Inclusion Criteria

• Inclusion Criteria:
• - Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening
• - T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication(s)
• - HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol)
• - Increased risk of cardiovascular (CV) events defined by ≥1 of: documented coronary heart disease, peripheral arterial disease, ischemic cerebrovascular disease, or heart failure (NYHA II–III); or ≥2 CV risk factors
• - Body mass index (BMI) of ≥ 23 kg/m2 at screening
• - Stable body weight (self-reported or documented) for 90 days prior to screening
• Exclusion Criteria:
• - Type 1 Diabetes Mellitus (T1DM), secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
• - Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
• - Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
• - Clinically significant condition affecting the upper Gastrointestinal (GI) tract or chronic use of any medication that affects gastric motility or gastric emptying
• - History of acute or chronic pancreatitis
• - Severe congestive heart failure (NYHA IV)
• - History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2